A Chronic Pain Patient Weighs Cannabinoid Therapy
Standard treatments failed. Cannabinoids are one option among several.
- ~20%: Chronic pain prevalence (of adults, high-income countries)
- 100+: Cannabinoid trial count (RCTs across pain types)
- 4: Pain types studied (neuropathic, MSK, inflammatory, other)
- Mixed: Regulatory status (varies sharply by jurisdiction)
Why evidence quality varies by pain type
Not all chronic pain is the same mechanism.
Evidence strength differs sharply by pain type.
This simulator sorts claims by pain category.
What "evidence-based" should mean here
Modest, real effects are not dramatic cures.
Context and pain type matter more than headlines.
Neuropathic Pain Has the Strongest Cannabinoid Evidence
Nerve-related chronic pain shows the most consistent trial signal.
- 68%: Evidence strength (all studies) (of trials show benefit signal)
- 58%: High-quality subset (after rigor filtering)
- Modest: Typical effect size (meaningful, not dramatic)
- Medium: Placebo confound (lower than other pain types)
Why nerve pain responds most consistently
Endocannabinoid signaling is dense in nociceptive pathways.
Several trials converge on modest neuropathic benefit.
Still not a first-line cure
Modest gains, useful as an add-on option.
Best evidence among pain types, not proof of cure.
Neuropathic pain remains the pain type with the clearest, most replicated cannabinoid signal.
Musculoskeletal and Inflammatory Pain: Weaker, Mixed Evidence
Outside neuropathic pain, cannabinoid trial results are inconsistent.
- 42%: Musculoskeletal evidence (all-studies strength score)
- 38%: Inflammatory evidence (all-studies strength score)
- 30%: Other chronic pain (weakest, most uncertain category)
- -14pt: High-quality drop-off (avg. strength loss after filtering)
Mixed trial outcomes across categories
Musculoskeletal pain trials show inconsistent, smaller effects.
Inflammatory pain results vary widely by study.
Fewer rigorous trials in these categories
Study quality drops evidence strength further here.
Expectations should be more tempered outside neuropathic pain.
Modest Effects, Substantial Placebo Response
Most trials show real but small gains, muddied by placebo response.
- Small–Modest: Typical effect size (across pooled trial data)
- 45–70%: Placebo response range (of reported pain reduction)
- ~10-14pt: Rigor-filtered strength drop (high-quality studies only)
- Majority: Trials with high placebo (especially non-neuropathic pain)
Separating real signal from placebo noise
Placebo response is large across chronic pain trials.
Effect sizes shrink once rigor filters are applied.
Quality filtering changes the picture
High-quality trials show smaller, still real benefits.
This is normal for pain research, not disqualifying.
A modest, real effect amid heavy placebo response is still a genuine signal — just not a large one.
One Reasonable Option — With Tempered Expectations Elsewhere
Cannabinoids fit best for refractory neuropathic pain, less so elsewhere.
- Neuropathic: Best-supported use case (pain unresponsive to other tx)
- Other chronic: Weakest use case (pain, most uncertain evidence)
- Modest, real: Overall verdict (not a broad cure-all)
- Adjunct option: Clinical framing (not first-line for most pain)
A defensible, narrow role
Reasonable second-line option for refractory neuropathic pain.
Not strongly supported as a general pain cure.
Setting expectations by pain type
Match expectations to the specific pain type in question.
Honest evidence framing beats one-size-fits-all claims.
The most defensible cannabinoid pain claim is narrow: modest benefit for neuropathic pain, not a general chronic-pain cure.